Article
Molnupiravir increases SARS-CoV-2 genome diversity and complexity: A case-control cohort study.
Journal of medical virology - 1 May 2024
Gruber Cesare Ernesto Maria, Tucci Fabio Giovanni, Giombini Emanuela, Mazzotta Valentina, Spezia Pietro Giorgio, Rueca Martina, Mastrorosa Ilaria, Fabeni Lavinia, Berno Giulia, Butera Ornella, Rosati Silvia, Specchiarello Eliana, Carletti Fabrizio, Focosi Daniele, Nicastri Emanuele, Girardi Enrico, Antinori Andrea, Maggi Fabrizio
Abstract excerpt
Molnupiravir, an oral direct-acting antiviral effective in vitro against SARS-CoV-2, has been largely employed during the COVID-19 pandemic, since December 2021. After marketing and widespread usage, a progressive increase in SARS-CoV-2 lineages characterized by a higher transition/transversion ratio, a characteristic signature of molnupiravir action, appeared in the Global Initiative on Sharing All Influenza...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.